ASX Company Announcements


The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange

 

12 Dec 2016 

 CxBladder update

29 Nov 2016 

 Cellmid Receives 831K R&D Tax Credit

21 Nov 2016

 Results of Annual General Meeting

21 Nov 2016 

 AGM Presentation by CEO

17 Nov 2016

 Appendix 3Y - Change of Director’s Interest Notice

09 Nov 2016

 Cleansing Statement - Notice under section 708A(5)(e) of the Corporations Act

3 Nov 2016

 Usa Launch of Évolis®

1 Nov 2016

 Appendix 3Y- Change of Director’s Interest Notice

1 Nov 2016

 ASX Market Release - Reinstatement

1 Nov 2016

 Cellmid Capital Raising

 1 Nov 2016

 Notes to Appendix 4C 

 28 Oct 2016

 Notes to the Appendix 3B

 26 Oct 2016

 Trading Halt

 25 Oct 2016

 Exercise of options (CDYO)

 21 Oct 2016

 Appendix 3B - New issue announcement

 19 Oct 2016

 Notice of Annual General Meeting

 18 Oct 2016

 Change of Directors Interest Notice - Edward Fintan Walton

 18 Oct 2016

 Change of Directors Interest Notice - Bruce Gordon

 18 Oct 2016

 Change of Directors Interest Notice - David King 

 18 Oct 2016

 Change of Directors Interest Notice - Maria Halasz

 10 Oct 2016

 Cellmid Records Highest Ever Quarterly Sales For Evolis®

 05 Oct 2016

 Cellmid's Midkine Antibodies Show Anti-tumor Activity Against Brain Cancer

 30 Sep 2016

 2016 Annual Report

 28 Sep 2016

 Quotation of Listed Options 

 23 Sep 2016

 Expiry of Listed Options (CDYO)

 22 Sep 2016

 European Midkine Patent for Surgical Adhesion Allowed

 19 Sep 2016

 Change of Directors Interest Notice - Maria Halasz

 13 Sep 2016 

 Date of Annual General Meeting

 31 Aug 2016

 Appendix 4G - Corporate Governance Statement

 31 Aug 2016

 Appendix 4E and Preliminary Final Report

 09 Aug 2016

 New publication for Cellmid's Midkine antibody

 03 Aug 2016

 Cellmid Investor Presentation

 29 Jul 2016

 Transcript of Cellmid Investor Briefing Call

 26 Jul 2016 

 Appendix 4C - quarterly

 22 Jul 2016

 Ikon Legal Action

 21 Jul 2016

 Cellmid Investor Briefing

 20 Jul 2016

 USA Distribution Partnership for Cellmid's évolis®

29 Jun 2016

 Midkine interviews with Pharmatelevision published

 24 Jun 2016

 MK antibody publication and patent in bone healing

 20 Jun 2016

 Change of Directors Interest Notice - Maria Halasz

 14 Jun 2016

 évolis Professional Launch

 26 May 2016

 Record monthly sales for Advangen Japan

 11 May 2016

 4th MK Symposium Results

 09 May 2016

 Significant scientific appointment for cellmid advisory board chair

 21 Apr 2016

 Appendix 4C - quarterly

 08 Apr 2016

 Midkine Strategy Update

 04 Apr 2016

 Fourth Midkine Symposium to be held in Budapest

 29 Feb 2016

 Transcript of Cellmid Investor Briefing

 26 Feb 2016

 Cellmid to Refinance RnD Loan

 25 Feb 2016

 Appendix 4D and Half Year Accounts

 23 Feb 2016

 Cellmid Investor Briefing

 04 Feb 2016

 Appointment of Elizabeth Masamune

 27 Jan 2016  

 Appendix 4C - quarterly